Q1 2017 13F Holders as of 3/31/2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236M
-
Number of holders
-
84
-
Total 13F shares, excl. options
-
20.8M
-
Shares change
-
+2.61M
-
Total reported value, excl. options
-
$191M
-
Value change
-
+$23.1M
-
Put/Call ratio
-
0.23
-
Number of buys
-
38
-
Number of sells
-
-42
-
Price
-
$9.20
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q1 2017
101 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q1 2017.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 84 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 20.8M shares
of 236M outstanding shares and own 8.82% of the company stock.
Largest 10 shareholders include EAGLE ASSET MANAGEMENT INC (3.55M shares), BlackRock Inc. (2.69M shares), Nantahala Capital Management, LLC (2.28M shares), VANGUARD GROUP INC (1.3M shares), Novo A/S (1.27M shares), FIRST MANHATTAN CO (1.04M shares), FMR LLC (932K shares), MORGAN STANLEY (870K shares), Marshall Wace North America L.P. (692K shares), and STATE STREET CORP (548K shares).
This table shows the top 84 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.